Estradiol-driven metabolism in transwomen associates with reduced circulating extracellular vesicle microRNA-224/452

Autor: Hetty C M Sips, Huayu Zhang, Patrick C.N. Rensen, Rienk Nieuwland, Ton J. Rabelink, Wendy Stam, Anton Jan van Zonneveld, Sander Kooijman, Maartje Klaver, Ronald W. A. L. Limpens, Barend W. Florijn, Martin den Heijer, Jurriën Prins, Maaike Hanegraaf, Roel Bijkerk, Jacques M.G.J. Duijs, Bas B. van Rijn, Eline N. Kuipers

Publikováno v: European Journal of Endocrinology, 185(4), 539-552. BioScientifica Ltd.
European Journal of Endocrinology, 185(4), 539-552. Bioscientifica Ltd
European Journal of Endocrinology
Florijn, B W, Duijs, J M G J, Klaver, M, Kuipers, E N, Kooijman, S, Prins, J, Zhang, H, Sips, H C M, Stam, W, Hanegraaf, M, Limpens, R W A L, Nieuwland, R, van Rijn, B B, Rabelink, T J, Rensen, P C N, den Heijer, M, Bijkerk, R & van Zonneveld, A J 2021, ' Estradiol-driven metabolism in transwomen associates with reduced circulating extracellular vesicle microRNA-224/452 ', European Journal of Endocrinology, vol. 185, no. 4, pp. 539-552 . https://doi.org/10.1530/EJE-21-0267
European Journal of Endocrinology, 185(4), 539-552. BIOSCIENTIFICA LTD

Objective Sex steroid hormones like estrogens have a key role in the regulation of energy homeostasis and metabolism. In transwomen, gender-affirming hormone therapy like estradiol (in combination with antiandrogenic compounds) could affect metabolis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adc0ba02da264f0cd6a21c389ba67297
https://research.vumc.nl/en/publications/24631769-627e-4df1-9dbc-1d5f8df68840

Pancreatic α-cell mass in obesity

Autor: Françoise Carlotti, Eelco J.P. de Koning, Hendrica A. M. Töns, Ton J. Rabelink, Maaike Hanegraaf, Marten A. Engelse, Johanne H. Ellenbroek

Publikováno v: Diabetes, Obesity and Metabolism, 19(12), 1810-1813. Wiley-Blackwell

While it is well recognized that obesity is associated with an increased β-cell mass, the association with α-cell mass is less clear. Type 2 diabetes (T2DM) associated with obesity is a bihormonal disease characterized by inadequate insulin secreti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e205ab39834ad28716df591d60f16b03
https://doi.org/10.1111/dom.12997

In Vivo Silencing of MicroRNA-132 Reduces Blood Glucose and Improves Insulin Secretion

Autor: Eelco J.P. de Koning, Johanne H. Ellenbroek, Anton Jan van Zonneveld, Roel Bijkerk, Yu Wah Au, Lena Eliasson, Maaike Hanegraaf, Jonathan L.S. Esguerra

Publikováno v: Nucleic Acid Therapeutics, 29(2), 67-72. Mary Ann Liebert Inc.
Nucleic Acid Therapeutics
Nucleic Acid Therapeutics, 29(2), 67-72. MARY ANN LIEBERT, INC

Dysfunctional insulin secretion is a hallmark of type 2 diabetes (T2D). Interestingly, several islet microRNAs (miRNAs) are upregulated in T2D, including miR-132. We aimed to investigate whether in vivo treatment with antagomir-132 lowers expression

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95e603bed7fb5ce5d616dc74a77afbad
https://pure.knaw.nl/portal/en/publications/36ac31b6-a044-4d2c-a002-f843da263d67

Coculturing human islets with proangiogenic support cells to improve islet revascularization at the subcutaneous transplantation site

Autor: Jan de Boer, Clemens van Blitterswijk, Marten A. Engelse, Aart A. van Apeldoorn, Jacqueline R. M. Plass, Marcel Karperien, Eelco J.P. de Koning, Maaike Hanegraaf, Mijke Buitinga, Dirk Jan Cornelissen, Françoise Carlotti, Karolina Janeczek Portalska

Publikováno v: Tissue engineering. Part A, 22(3 en 4), 375-385. Mary Ann Liebert Inc.
Tissue engineering. Part A, 22(3-4), 375-85. Mary Ann Liebert Inc.
Tissue Engineering: Parts A, B, and C, 22(3-4), 375-385. MARY ANN LIEBERT, INC
Tissue Engineering. Part A, 22(3-4), 375. Mary Ann Liebert Inc.
Tissue Engineering, 22(3-4), 375-385. Mary Ann Liebert Inc.

While subcutaneous tissue has been proposed as a clinically relevant site for pancreatic islet transplantation, a major issue of concern remains, which is its poor vascular state. In an effort to overcome this limitation, we present an efficient and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9de7faaf25ea49be43aa4b60204866fd
https://research.utwente.nl/en/publications/366ea8ec-f379-4d3f-a7c5-efe5a3c09f1f

PS2 - 8. Liraglutide decreases beta-cell mass in normoglycemic and high-fat diet-fed mice

Autor: Françoise Carlotti, Menso Westerouen van Meeteren, Rianne Ellenbroek, Ton J. Rabelink, Eelco J.P. de Koning, Annemieke Töns, Natascha de Graaf, Maaike Hanegraaf

Publikováno v: Nederlands Tijdschrift voor Diabetologie. 10:104-105

Incretin-based therapies are used to treat patients with type 2 diabetes by stimulating insulin secretion. The incretin glucagon-like-peptide-1 (GLP-1) also increases beta-cell mass in diabetic animal models. GLP-1 receptor agonists also decrease bod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b54e1f3715aebfd89afef8e7416e9f7f
https://doi.org/10.1007/s12467-012-0042-y